

ALLEGATO B

UNIVERSITÀ DEGLI STUDI DI MILANO

selezione pubblica per n. 1 posto/i di Ricercatore a tempo determinato ai sensi dell'art.24, comma 3, lettera a) della Legge 240/2010 nell'ambito del Piano Nazionale di Ripresa e Resilienza (PNRR), per il settore concorsuale 05/G1 - FARMACOLOGIA, FARMACOLOGIA CLINICA E FARMACOGNOSIA, settore scientifico-disciplinare BIO/14 presso il Dipartimento di Scienze della Salute (avviso bando pubblicato sulla G.U. n. 10 del 07/02/2023) Codice concorso 5227

Mirco Masi **CURRICULUM VITAE**

(N.B. IL CURRICULUM NON DEVE ECCEDERE LE 30 PAGINE E DEVE CONTENERE GLI ELEMENTI CHE IL CANDIDATO RITIENE UTILI AI FINI DELLA VALUTAZIONE.

LE VOCI INSERITE NEL FACSIMILE SONO A TITOLO PURAMENTE ESEMPLIFICATIVO E POSSONO ESSERE SOSTITUITE, MODIFICATE O INTEGRATE)

INFORMAZIONI PERSONALI (NON INSERIRE INDIRIZZO PRIVATO E TELEFONO FISSO O CELLULARE)

| | |
|-----------------|------------|
| COGNOME | MASI |
| NOME | MIRCO |
| DATA DI NASCITA | 01/02/1994 |

TITOLI

TITOLO DI STUDIO

(indicare la Laurea conseguita inserendo titolo, Ateneo, data di conseguimento, ecc.)

18/10/2018 - Master of Science (MSc), Pharmaceutical Biotechnology, 110/110 with honours, Alma Mater Studiorum - University of Bologna, School of Pharmacy and Biotechnology. Thesis title: "Assaying the regulation of the mitotic machinery using CRISPR/Cas9 gene targeting and live cell microscopy"

21/07/2016 - Bachelor of Science (BSc), Biotechnology, 110/110 with honours, Alma Mater Studiorum - University of Bologna, School of Pharmacy and Biotechnology. Thesis title: "The role of Arrestin 3 in intracellular signal transduction induced by different opioid kappa receptor (KOR) agonists"

TITOLO DI DOTTORE DI RICERCA O EQUIVALENTI, OVVERO, PER I SETTORI INTERESSATI, DEL DIPLOMA DI SPECIALIZZAZIONE MEDICA O EQUIVALENTE, CONSEGUITO IN ITALIA O ALL'ESTERO

(inserire titolo, ente, data di conseguimento, ecc.)

23/06/2022 - PhD in Biomolecular Sciences and Biotechnologies, University School for Advanced Studies IUSS - Pavia. Thesis title: "The Pharmacological and Toxicological Implications of Hormone-Mediated RACK1 Transcriptional Regulation"

CONTRATTI DI RICERCA, ASSEGNI DI RICERCA O EQUIVALENTI

(per ciascun contratto stipulato, inserire università/ente, data di inizio e fine, ecc.)

From 04/2022 to Today - Post Doctoral Researcher in Cellular and Molecular Cancer Biology, Italian Institute of Technology (IIT), Genoa

From 10/2018 to 03/2022 - PhD student Laboratory of Biology and Pharmacology of Aging, Inflammation, Cancer and Neurodegeneration, University of Pavia, Pavia (IT), Department of Drug Sciences

From 03/2018 to 09/2018 - MSc Intern in the Cancer Biology Division Internship ICR, Institute of Cancer Research - London (UK)

From 03/2016 to 07/2016 - BSc Intern in the Laboratory of Cellular and Molecular Pharmacology, Alma Mater Studiorum - University of Bologna, Bologna (IT), Department of Pharmacology

ATTIVITÀ DIDATTICA A LIVELLO UNIVERSITARIO IN ITALIA O ALL'ESTERO

(inserire anno accademico, ateneo, corso laurea, numero ore, ecc.)

LECTURES:

AA 2021/2022, University of Pavia, Faculty of Pharmacy, 4 hours/year. Lecture: "Drugs for the Respiratory System: Pharmacological Therapy for Asthma and Chronic Obstructive Pulmonary Disease (COPD)" (in co-presence with Prof. Annalisa Barbieri and Prof. Erica Buoso) - 21st-22nd December 2021

TUTORING:

AA 2019/2020, University of Pavia, Faculty of Pharmaceutical Chemistry and Technologies, Laboratory of Applied and Experimental Pharmacology (with Prof. Marco Racchi and Assistant Prof. Cristina Travelli), 40 hours

THESIS CO-SUPERVISOR:

10/2022 - Experimental thesis "DLST-dependence induces differential TCA cycle usage providing therapeutic implications in Triple Negative Breast Cancer", by André Fiou, Faculty of Pharmacy (MSc) - University of Pavia

10/2022 - Compilation thesis "Tau alternative splicing, ribosome impairment and stress granules: triome landscape for multi-target pharmacologic approach in Alzheimer's disease", by Giada Zambelli, Faculty of Pharmacy (MSc) - University of Pavia

07/2022 - Experimental thesis "OXER1-Associated Signaling Pathway as a Possible Drug Target in Triple Negative Breast Cancer", by Ilaria Robustellini, Faculty of Pharmaceutical Chemistry and Technologies (MSc) - University of Pavia

06/2022 - Experimental thesis "Direct and Indirect Endocrine Effects of Contaminating Pesticides on RACK1 Expression and their Immunological Consequences in THP-1 Cells", by Vittoria Licari, Faculty of Medical and Pharmaceutical Biotechnologies (MSc) - University of Pavia

10/2021 - Experimental thesis "OXER1-Associated Signalling Pathway as a Potential Drug Target for Triple Negative Breast Cancer", by Laura Alberti, Faculty of Pharmacy (MSc) - University of Pavia

04/2021 - Experimental thesis "The Glucocorticoid Role in Depression: Emerging Contribution of RACK1", by Alessia Picozzi, Faculty of Neurobiology (MSc) - University of Pavia

09/2020 - Experimental thesis “Ribosome impairment as a nexus between translation and neurodegeneration: focus on RACK1 in Alzheimer’s disease”, by Valeria Melpignano”, Faculty of Experimental and Applied Biology (MSc) - University of Pavia

07/2020 - Experimental thesis “OXER1: a new androgen receptor involved in RACK1 transcriptional regulation for breast cancer progression”, by Luisa Maraccani, Faculty of Pharmaceutical Chemistry and Technology (MSc) - University of Pavia

04/2020 - Experimental thesis “Endocrine Disrupting Chemicals (EDCs) effect on RACK1 transcriptional regulation” by Margherita Zanazzi, Faculty of Biotechnologies (BSc) - University of Pavia

02/2020 - Experimental thesis “RACK1 mutants and their possible effects in breast cancer cells” by Daisy Lenea, Faculty of Biotechnologies (BSc) - University of Pavia

09/2019 - Experimental thesis “RACK1 promotes breast cancer cell growth via MCM7/RACK1 signaling complex”, by Aleksandra Chlebowska (Erasmus Student), Faculty of Pharmacy and Medicine Division (MSc) - Medical University of Gdańsk

09/2019 - Compilation thesis “Interaction between SGs and RACK1 and their role in cancer and neurodegeneration”, by Sofia Borella, Faculty of Biotechnologies (BSc) - University of Pavia

DOCUMENTATA ATTIVITÀ DI FORMAZIONE O DI RICERCA PRESSO QUALIFICATI ISTITUTI ITALIANI O STRANIERI;

(inserire anno accademico, ente, corso, periodo, ecc.)

04/2022 - Today - Italian Institute of Technology (IIT) - Genova, Computational and Chemical Biology, under the supervision of Prof. Andrea Cavalli.

10/2018 - 03/2022 - University School for Advanced Studies IUSS Pavia/ University of Pavia, Laboratory of Biology and Pharmacology of Aging, Inflammation, Cancer and Neurodegeneration under the supervision of Prof. Stefano Govoni, Prof. Marco Racchi and Prof. Erica Buoso.

AA 2017-2018, 03/2018 - 09/2018 - ICR Institute of Cancer Research - London, Cancer Biology Division Internship, Cell Division under the supervision of Prof. Jonathon Pines.

AA 2015-2016, 03/2016 - 07/2016 - Alma Mater Studiorum - University of Bologna, Laboratory of Cellular and Molecular Pharmacology Internship under the supervision of Prof. Andrea Bedini.

DOCUMENTATA ATTIVITÀ IN CAMPO CLINICO

(indicare, data, durata, ruolo, ente presso il quale si è prestata attività assistenziale, ecc.)

| |
|--|
| |
|--|

REALIZZAZIONE DI ATTIVITÀ PROGETTUALE

(indicare, data, progetto, ecc.)

Winner of a Three-year (2023-2025) AIRC Fellowship - Italy Post-Doc 2022 for the project “Synthetic Lethality in BRCAness: exploring innovative mechanisms linked to RAD52” (Project Code: 28174) carried out at the Italian Institute of Technology

ORGANIZZAZIONE, DIREZIONE E COORDINAMENTO DI GRUPPI DI RICERCA NAZIONALI E INTERNAZIONALI, O PARTECIPAZIONE AGLI STESSI

(per ciascuna voce inserire anno, ruolo, gruppo di ricerca, ecc.)

Member, as Post Doctoral Researcher, of the Research Group of Computational and Chemical Biology of IIT Genova for the Individual Grant from Associazione Italiana per la Ricerca sul Cancro AIRC (IG Project 2018, id 21386, EPFD0106) entitled "A chemical biology approach to synthetic lethality by means of DNA repair inhibitors". Scientific Coordinator Prof. Andrea Cavalli, Scientific Manager Dr. Stefania Giroto.

Member, as PhD student, of the Research Unit of Pavia for the "Programma di Ricerca PRIN 2020" (Project number 202039WMFP) entitled "New interventional approaches on multiple inflammatory pathways involved in regeneration after trauma and aging-associated diseases". Scientific Coordinator Prof. Salvatore Cuzzocrea, Scientific Manager Prof. Marco Racchi.

Member, as PhD student, of the Research Unit of Pavia for the "Programma di Ricerca PRIN 2020" (Project number 2020SEMP22) entitled "Regulation of autophagy by N-acyl ethanolamines as a promising approach for the treatment of inflammatory-based diseases: from neurodegeneration to metabolic disorders". Scientific Coordinator Prof. Irene Paterniti, Scientific Manager Prof. Cristina Travelli.

Member, as PhD student, of the Research Unit of Pavia for the "Programma di Ricerca PRIN 2017" (Project number 2017MLC3NF) entitled "Endocrine disruptors: investigation of the effects on the immune and nervous systems (EDoNIS)". Scientific Coordinator Prof. Emanuela Corsini, Scientific Manager Prof. Erica Buoso.

Member, as PhD student, of the Research Unit of Pavia for the "Programma di Ricerca PRIN 2017" (Project number 2017B9NCSX) entitled "Study of the crosstalk between multiple pathways in the regulation of inflammatory processes in models of chronic and degenerative diseases". Scientific Coordinator Prof. Salvatore Cuzzocrea, Scientific Manager Prof. Marco Racchi.

TITOLARITÀ DI BREVETTI

(per ciascun brevetto, inserire autori, titolo, tipologia, numero brevetto, ecc.)

| |
|--|
| |
|--|

ATTIVITÀ DI RELATORE A CONGRESSI E CONVEGNI NAZIONALI E INTERNAZIONALI

(inserire titolo congresso/convegno, data, ecc.)

02/2023 - Masi M, Loss of RACK1-related maintenance of epithelial barrier integrity in inflammatory bowel diseases is restored upon dexamethasone treatment in vitro. SIF Monothematic Conference "Nuove strategie terapeutiche per il trattamento delle patologie algiche intestinali", February 16th-17th 2023, Florence

11/2022 - Masi M, Immunological implications of Endocrine Disrupting Chemicals (EDCs): RACK1 as a bridge between the endocrine and the immune systems. XXIV SIF Seminar on Pharmacology for PhD Students, Fellows, Post Doc and Specialist Trainees, November 15th-16th 2022, Rome, Session: Pharmacognosy and Toxicology

09/2022 - Masi M, A Promising Druggable Target in Breast Cancer (BC) Progression: Oxoeicosanoid Receptor 1 (OXER1) and Receptor for Activated C Kinase 1 (RACK1)-Associated Pathway. Rapid Response to Steroid Hormones RRSB - 13th International Meeting on Rapid Responses to Steroid Hormones, Paris 20th-23rd September 2022

08/2022 - Masi M, OXER1 and RACK1-associated pathway: a promising drug target in Triple-Negative Breast Cancer and its emerging role in Tumour Microenvironment. European Endocrinology and Diabetes Congress, August 22nd-23rd 2022

11/2021 - Masi M, Immune Response and Endocrine Disrupting Chemicals (EDCs): RACK1 as a Bridge between the Endocrine and the Immune Systems. SIF Immunopharmacology Working Group Meeting, Perugia 24-26th November 2021

08/2021 - Masi M, Immunological implications of Endocrine Disrupting Chemicals (EDCs): Emerging role of RACK1 as EDCs screening tool. European Endocrinology and Diabetes Congress, August 5th 2021

07/2021 - Masi M, Oxoeicosanoid Receptor 1 (OXER1) and Receptor for Activated C Kinase 1 (RACK1)-Associated Pathway: A Promising Drug Target In Breast Cancer Progression. World Cancer Research and Therapy Webinar - WCCRT 8th Edition, July 14th 2021

03/2021 - Masi M, Effects of Endocrine Disrupting Chemicals (EDCs) on RACK1 Expression and their Immunological Implications. XXIII SIF Seminar on Pharmacology for PhD Students, Fellows, Post Doc and Specialist Trainees - Digital Edition, March 8th 2021, Room 4, Session 8: Basic and Clinical research

CONSEGUIMENTO DI PREMI E RICONOSCIMENTI NAZIONALI E INTERNAZIONALI PER ATTIVITÀ DI RICERCA (inserire premio, data, ente organizzatore, ecc.)

Three-year (2023-2025) AIRC Fellowship - Italy Post-Doc 2022 for the project "Synthetic Lethality in BRCAness: exploring innovative mechanisms linked to RAD52" carried out at the Italian Institute of Technology (Genoa) (105.000,00 €)

SIF Scholarship for the best Oral Communications presented in the XXIII SIF Seminar (March 8th 2021) and in the 40° Società Italiana di Farmacologia (SIF) National Congress (March 9th-13th 2021) - Digital Edition (500,00 €)

Short-term Scholarship for Master Thesis internship, Alma Mater Studiorum University of Bologna, IT - 6 months in Prof. Jonathon Pines, Cancer Biology Division, ICR - Institute of Cancer Research, London, UK (2400 €)

POSSESSO DEL DIPLOMA DI SPECIALIZZAZIONE EUROPEA RICONOSCIUTO DA BOARD INTERNAZIONALI (relativamente a quei settori concorsuali nei quali è prevista) (indicare diploma, data di conseguimento, ecc.)

TITOLI DI CUI ALL'ARTICOLO 24 COMMA 3 LETTERA A) E B) DELLA LEGGE 30 DICEMBRE 2010, N. 240 (indicare se contratto di tipologia A o B, Ateneo, data di decorrenza e fine contratto, ecc.)

CAPACITÀ E COMPETENZE TECNICHE

Tissue Culture: generation, culturing and maintenance of immortalized cell lines. Specific expertise for the following cell lines: MDA-MB-231, MCF-7, HCC1187, CAL-85-1, ZR-75-1 and MCF10A (breast cancer); THP-1 (leukemic monocytes); SH-SY5Y (neuroblastoma); BxPC-3 and Capan-1 (pancreatic cancer); HEK293; RPE-1 and ARPE-1 (retinal pigment epithelial cells); HaCaT (human keratinocyte); HeLa (human cervical carcinoma); Caco-2 (colorectal adenocarcinoma).

Microscopy: optical, fluorescent and confocal.

Molecular biology techniques: Extraction, purification and quantification of nucleic acids, cloning, luciferase reporter assays, end-point PCR, reverse-transcription PCR (RT-PCR), quantitative PCR (qPCR), CRISPR/Cas9, Reverse-Transcription, cell transfection plasmid production, adenoviral vectors production.

Biochemistry techniques: SDS-PAGE, immunoblot, cell lysis and protein quantification, cell viability assays, immunofluorescence, immunoprecipitation.

Microbiology techniques: Solid (agar) and liquid bacterial cultures, bacterial cells transformation.

Spectroscopy techniques: Spectrophotometry for absorbance detection.

Informatic and bioinformatic expertise: Microsoft Office/Open Office, Adobe, ImageJ Fiji, GraphPad Prism, database query for similar sequence research and alignment.

CORSI DI FORMAZIONE SPECIFICI

02/2021 - CRISPR: Revolutionising Genome Editing Certificate Program - CRISPR Biotech Engineering LTD (Molecular Biology and Translational studies)

06/2017 - Summer School "Chemical and Genomics Based Strategies in The Discovery of Novel Drug Targets" - Alma Mater Studiorum University of Bologna

LINGUE STRANIERE CONOSCIUTE

English: C1 level (7.5 IELTS)
French: B1 level

PRODUZIONE SCIENTIFICA

PUBBLICAZIONI SCIENTIFICHE

(per ciascuna pubblicazione indicare: nomi degli autori, titolo completo, casa editrice, data e luogo di pubblicazione, codice ISBN, ISSN, DOI o altro equivalente)

SCIENTIFIC ARTICLES ON PEER-REVIEWED JOURNALS:

Balboni B, Masi M, Girotto S, Rocchia W, Cavalli A. GSK-3B and allosterism: towards new pharmacological frontiers? *Submitted to IJMS as of February 2023.*

Masi M, Biundo F, Fiou A, Racchi M, Pascale A, Buoso E. The labyrinthine landscape of APP processing: state of the art and possible novel soluble APP-related molecular players in traumatic brain injury and neurodegeneration. *Submitted to IJMS as of February 2023.*

Masi M*, Maddalon A*, Iulini M, Linciano P, Galbiati V, Marinovich M, Racchi M, Corsini E, Buoso E. Effects of endocrine disrupting chemicals on the expression of RACK1 and LPS-induced THP-1 cell activation. *Toxicology. 2022 Sep 13;480:153321. doi: 10.1016/j.tox.2022.153321. (*These authors contributed equally). IF = 4.571, Q1, Citations = 1*

Maddalon A*, Masi M*, Iulini M, Linciano P, Galbiati V, Marinovich M, Racchi M, Buoso E, Corsini E. Effects of endocrine active contaminating pesticides on RACK1 expression and immunological consequences in THP-1 cells. *Environ Toxicol Pharmacol. 2022 Sep 6;95:103971. doi: 10.1016/j.etap.2022.103971. (*These authors contributed equally). IF = 5.45, Q1*

Masi M*, Attanzio A*, Racchi M, Wolozin B, Borella S, Biundo F, Buoso E. Proteostasis Deregulation in Neurodegeneration and Its Link with Stress Granules: Focus on the Scaffold and Ribosomal Protein

RACK1. Cells. 2022 Aug 19;11(16):2590. doi: 10.3390/cells11162590. (*These authors contributed equally). IF = 7.666, Q1, Citations = 2

Masi M, Racchi M, Travelli C, Corsini E, Buoso E. Molecular Characterization of Membrane Steroid Receptors in Hormone-Sensitive Cancers. Cells. 2021 Nov 3;10(11):2999. doi: 10.3390/cells10112999. IF = 7.666, Q1, Citations = 9

Buoso E*, Kenda M*, Masi M, Linciano P, Galbiati V, Racchi M, Dolenc MS, Corsini E. Effects of Bisphenols on RACK1 Expression and Their Immunological Implications in THP-1 Cells. Front Pharmacol. 2021 Sep 21;12:743991. doi: 10.3389/fphar.2021.743991. (*These authors contributed equally). IF = 5.811, Q1, Citations = 6

Brivio P*, Buoso E*, Masi M, Gallo MT, Gruca P, Lason M, Litwa E, Papp M, Fumagalli F, Racchi M, Corsini E, Calabrese F. The coupling of RACK1 with the beta isoform of the glucocorticoid receptor promotes resilience to chronic stress exposure. Neurobiol Stress. 2021 Jul 26;15:100372. doi: 10.1016/j.ynstr.2021.100372. (*These authors contributed equally). IF = 6.49, Q1, Citations = 5

Masi M, Garattini E, Bolis M, Di Marino D, Maraccani L, Morelli E, Grolla AA, Fagiani F, Corsini E, Travelli C, Govoni S, Racchi M, Buoso E. OXER1 and RACK1-associated pathway: a promising drug target for breast cancer progression. Oncogenesis. 2020 Dec 11;9(12):105. doi: 10.1038/s41389-020-00291-x. IF = 7.485, Q1, Citations = 21

Buoso E*, Masi M*, Racchi M, Corsini E. Endocrine-Disrupting Chemicals' (EDCs) Effects on Tumour Microenvironment and Cancer Progression: Emerging Contribution of RACK1. Int J Mol Sci. 2020 Dec 3;21(23):9229. doi: 10.3390/ijms21239229. (*These authors contributed equally). IF = 5.924, Q1, Citations = 18

Buoso E, Masi M, Long A, Chiappini C, Travelli C, Govoni S, Racchi M. Ribosomes as a nexus between translation and cancer progression: Focus on ribosomal Receptor for Activated C Kinase 1 (RACK1) in breast cancer. Br J Pharmacol. 2022 Jun;179(12):2813-2828. doi: 10.1111/bph.15218. IF = 9.473, Q1, Citations = 13

Lanni C, Masi M, Racchi M, Govoni S. Cancer and Alzheimer's disease inverse relationship: an age-associated diverging derailment of shared pathways. Mol Psychiatry. 2021 Jan;26(1):280-295. doi: 10.1038/s41380-020-0760-2. IF = 15.992, Q1, Citations = 53

Buoso E, Masi M, Galbiati V, Maddalon A, Iulini M, Kenda M, Sollner Dolenc M, Marinovich M, Racchi M, Corsini E. Effect of estrogen-active compounds on the expression of RACK1 and immunological implications. Arch Toxicol. 2020 Jun;94(6):2081-2095. doi: 10.1007/s00204-020-02756-9. IF = 5.153, Q1, Citations = 12

METRIC SYNOPSIS OF THE ABOVE SCIENTIFIC ARTICLES PUBLISHED IN PEER-REVIEWED JOURNALS:

Total Impact Factor (referred to publication year) = 81.681

Average Impact Factor = 7.425

First/Co-First Author = 6/11

Second Author = 5/11

Total Citations (Google Scholar) = 140

h-index (Google Scholar) = 6

BOOK CHAPTERS:

Travelli C, Buoso E, Masi M. Chemioterapia antitumorale classica in "Farmacologia, a cura di Govoni, Spampinato et al. - Nuova Edizione", *scheduled publishshing June 2023*.

Travelli C, Buoso E, Masi M. Chemioterapia antitumorale: dalla terapia endocrina ai farmaci biologici e immunoterapici, alle terapie cellulari in "Farmacologia, a cura di Govoni, Spampinato et al. - Nuova Edizione" *scheduled publishshing June 2023*.

CONFERENCE PROCEEDINGS:

Masi M, Buoso Erica, Valentina Galbiati, Ambra Maddalon, Martina Iulini, Marina Marinovich, Marco Racchi, Emanuela Corsini (2022). "Immunological implications of Endocrine Disrupting Chemicals (EDCs): RACK1 as a bridge between the endocrine and the immune systems". Proceedings - The scientific value and appropriate use of drugs 2022. Vol. 5 (No. 2-Special) 2023 January. AA.VV. Abstracts, 251-404 doi: 10.36118/pharmadvances.2023.50

Buoso E, Masi M, Garattini E, Bolis M, di Marino D, Robustellini I, Corsini E, Travelli C, Racchi M. "Oxoecosanoid Receptor 1 (OXER1) emerging role as a promising druggable target in Triple Negative Breast Cancer (TNBC)". Proceedings - The scientific value and appropriate use of drugs 2022. Vol. 5 (No. 2-Special) 2023 January. AA.VV. Abstracts, 7-250 doi: 10.36118/pharmadvances.2023.50

Masi M, Buoso E, Galbiati V, Maddalon A, Iulini M, Marinovich M, Racchi M, Corsini E (2021). "Effects of Endocrine Disrupting Chemicals (EDCs) on RACK1 Expression and Their Immunological Implication". Proceedings - The scientific value and appropriate use of drugs 2021. Vol. 3 (No. 1) 2021 March. Proceedings, 3-347 doi: 10.36118/pharmadvances.03.2021.02

Buoso E, **Masi M**, Bolis M, di Marino D, Maraccani L, Morelli E, Grolla A. A, Fagiani F, Govoni S, Corsini E, Travelli C, Garattini E, Racchi M (2021). "Druggable Target Oxoecosanoid Receptor 1 (OXER1) and its RACK1-Associated Pathway in Breast Cancer Progression". Proceedings - The scientific value and appropriate use of drugs 2021. Vol. 3 (No. 1) 2021 March. Proceedings, 3-347 doi: 10.36118/pharmadvances.03.2021.02

POSTERS:

Buoso E, Ronfani M, **Masi M**, et al. Role of RACK1 mediated signalling in breast cancer cells migration/metastasis. 39° Congresso Nazionale della Società Italiana di Farmacologia (SIF), November 21st 2019, Poster Session 2, Totem nr. 8, P.244

REVIEWER ACTIVITY:

(2022) Cancers (ISSN 2072-6694), 2 articles

(2022) Current Oncology (ISSN 1718-7729), 1 article

(2022) Journal of Personalized Medicine (ISSN 2075-4426), 1 article

(2022) Frontiers in Public Health (ISSN 2296-2565), 1 article

(2021) Oxidative Medicine and Cellular Longevity (ISSN 1942-0994), 1 article

(2022) Journal of Zhejiang University - SCIENCE B (ISSN 1673-1581), 1 article

Data

21/02/2023

Luogo

Genova